endofocusFOCUS ЭндокринологияFOCUS. Endocrinology2713-01772713-0185ООО "Издательство "Перо"10.62751/2713-0177-2024-5-1-06endofocus-85Research ArticleОБЗОР ЛИТЕРАТУРЫLITERATURE REVIEWОбзор международных клинических рекомендаций по управлению артериальной гипертензией у пациентов с сахарным диабетомReview of international clinical guidelines for the management of hypertension in patients with diabetes mellitus?https://orcid.org/0000-0001-5512-6899УшановаФ. О.UshanovaF. O.

Ушанова Фатима Омариевна –   к.  м.  н., доцент кафедры эндокринологии лечебного факультета

117997, г. Москва, ул. Островитянова, д. 1

Fatima O.  Ushanova –  C. Sci. (Med.)

Ostrovitianov str. 1, Moscow, 117997

fati_2526@mail.ruhttps://orcid.org/0000-0001-6385-540XДемидоваТ. Ю.DemidovaT. Yu.

Демидова Татьяна Юльевна  –  д.  м.  н., профессор, заведующая кафедрой эндокринологии лечебного факультета

117997, г. Москва, ул. Островитянова, д. 1

Tatiana Yu.  Demidova –  D. Sci. (Med.), Prof.

Ostrovitianov str. 1, Moscow, 117997

t.y.demidova@gmail.comhttps://orcid.org/0009-0003-4222-8695ПантелееваС. В.PanteleevaS. V.

Пантелеева Софья Викторовна –  клинический ординатор кафедры эндокринологии лечебного факультета

117997, г. Москва, ул. Островитянова, д. 1

Sofia V.  Panteleeva –  clinical resident

Ostrovitianov str. 1, Moscow, 117997

sofia7652809@mail.ruФГАОУ ВО «РНИМУ им. Н. И. Пирогова» Минздрава РоссииPirogov Russian National Research Medical University202407052024514251Copyright © Ушанова Ф.О., Демидова Т.Ю., Пантелеева С.В., 20242024Ушанова Ф.О., Демидова Т.Ю., Пантелеева С.В.Ushanova F.O., Demidova T.Y., Panteleeva S.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://endofocus.elpub.ru/jour/article/view/85

Артериальная гипертензия (АГ) является одной из ведущих проблем кардиологических сообществ по всему миру. У больных сахарным диабетом  (СД) АГ встречается в 2 раза чаще, чем в общей популяции, являясь взаимоотягощающими заболеваниями и ведущими факторами риска развития ишемической болезни сердца, инсульта, застойной сердечной недостаточности и хронической болезни почек,  которые приводят к инвалидизации и увеличению сердечно- сосудистой смертности. Различные кардиологические  и эндокринологические сообщества уделяют особое внимание ведению АГ у пациентов с СД с учетом коморбидности. В представленном обзоре рассматриваются современные подходы к ведению АГ у больных СД на основе актуальных  международных клинических рекомендаций. Большинство действующих практических руководств и клинических рекомендаций подчеркивают необходимость ранней комбинированной антигипертензивной терапии при СД, что обусловлено  сложным многофакторным патогенезом и более тяжелым течением АГ при нарушениях  углеводного обмена. К основным группам антигипертензивных препаратов, рекомендованных при СД,  относятся: ингибиторы ангиотензинпревращающего фермента/блокаторы рецепторов ангиотензина, тиазидные/тиазидоподобные диуретики, антагонисты кальция.

Arterial hypertension (AH) is one of the leading problems of cardiological communities around the world. In patients with diabetes mellitus (DM), hypertension occurs 2 times more often than in the general population, being mutually aggravating diseases and leading risk factors for coronary heart disease, stroke, congestive heart failure and chronic kidney disease, which lead to disability and increased cardiovascular mortality. Various cardiological and endocrinological communities pay special attention to the management of hypertension in patients with DM, taking into account comorbidity. The present review examines modern approaches to the management of hypertension in DM patients based on current international clinical recommendations. Most of the current practical guidelines and clinical recommendations emphasize the need for early combined antihypertensive therapy for diabetes, which is due to the complex multifactorial pathogenesis and a more severe course of hypertension in disorders of carbohydrate metabolism. The main groups of antihypertensive drugs recommended for diabetes include: angiotensin converting enzyme inhibitors/angiotensin receptor blockers, thiazide/thiazide-like diuretics, calcium antagonists.

артериальная гипертензиясахарный диабетрезистентная артериальная гипертензияартериальное давлениеингибиторы ангиотензинпревращающего ферментаблокаторы рецепторов ангиотензинатиазидные/тиазидоподобные диуретикиhypertensiondiabetes mellitusresistant hypertensionblood pressureangiotensin converting enzyme inhibitorsangiotensin receptor blockersthiazide/thiazide-like diureticscalcium antagonistsReferencesMoick S, Sommer I, Gartlehner G. WHO-Leitlinie: Leitfaden für die medikamentöse Behandlung von Bluthochdruck bei Erwachsenen [WHO Guideline for the Pharmacological Treatment of Hypertension in Adults]. Gesundheitswesen. 2023 Feb;85(2):139–142. German. doi: 10.1055/a-1989-1745.Moick S, Sommer I, Gartlehner G. WHO-Leitlinie: Leitfaden für die medikamentöse Behandlung von Bluthochdruck bei Erwachsenen [WHO Guideline for the Pharmacological Treatment of Hypertension in Adults]. Gesundheitswesen. 2023 Feb;85(2):139–142. German. doi: 10.1055/a-1989-1745.Kagan A, Dawber TR, Kannel WB, Revotskie N. The Framingham study: a prospective study of coronary heart disease. Fed Proc. 1962 Jul-Aug;21(4) Pt 2:52–7. PMID: 14453051.Kagan A, Dawber TR, Kannel WB, Revotskie N. The Framingham study: a prospective study of coronary heart disease. Fed Proc. 1962 Jul-Aug;21(4) Pt 2:52–7. PMID: 14453051.Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018 Jun;71(6):1269–1324. doi: 10.1161/HYP.0000000000000066.Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018 Jun;71(6):1269–1324. doi: 10.1161/HYP.0000000000000066.Mancia G, Kreutz R, Brunström M, Burnier M, Grassi G, Januszewicz A, et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens. 2023 Dec 1;41(12):1874–2071. doi: 10.1097/HJH.0000000000003480.Mancia G, Kreutz R, Brunström M, Burnier M, Grassi G, Januszewicz A, et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens. 2023 Dec 1;41(12):1874–2071. doi: 10.1097/HJH.0000000000003480.Кобалава Ж. Д., Конради А. О., Недогода С. В., Шляхто Е. В., Арутюнов Г. П., Баранова Е. И. и др. Артериальная гипертензия у взрослых. Клинические рекомендации 2020. Российский кардиологический журнал. 2020; 25(3):3786. https://doi.org/10.15829/1560–4071–2020–3–3786.Кобалава Ж. Д., Конради А. О., Недогода С. В., Шляхто Е. В., Арутюнов Г. П., Баранова Е. И. и др. Артериальная гипертензия у взрослых. Клинические рекомендации 2020. Российский кардиологический журнал. 2020; 25(3):3786. https://doi.org/10.15829/1560–4071–2020–3–3786.Алгоритмы специализированной медицинской помощи больным сахарным диабетом / Под редакцией И. И. Дедова, М. В. Шестаковой, А. Ю. Майорова. – 11-й выпуск. – М.; 2023. doi: https://doi.org/10.14341/DM13042.Алгоритмы специализированной медицинской помощи больным сахарным диабетом / Под редакцией И. И. Дедова, М. В. Шестаковой, А. Ю. Майорова. – 11-й выпуск. – М.; 2023. doi: https://doi.org/10.14341/DM13042.American Diabetes Association Professional Practice Committee; Introduction and Methodology: Standards of Care in Diabetes-2024. Diabetes Care 1 January 2024; 47 (Supplement_1): S1–S4. https://doi.org/10.2337/dc24-SINT.American Diabetes Association Professional Practice Committee; Introduction and Methodology: Standards of Care in Diabetes-2024. Diabetes Care 1 January 2024; 47 (Supplement_1): S1–S4. https://doi.org/10.2337/dc24-SINT.King P, Peacock I, Donnelly R. The UK prospective diabetes study (UKPDS): clinical and therapeutic implications for type 2 diabetes. Br J Clin Pharmacol. 1999 Nov;48(5):643–8. doi: 10.1046/j.1365-2125.1999.00092.x.King P, Peacock I, Donnelly R. The UK prospective diabetes study (UKPDS): clinical and therapeutic implications for type 2 diabetes. Br J Clin Pharmacol. 1999 Nov;48(5):643–8. doi: 10.1046/j.1365-2125.1999.00092.x.Gorostidi, M., de la Sierra, A., González-Albarrán, O. et al. Abnormalities in ambulatory blood pressure monitoring in hypertensive patients with diabetes. Hypertens Res 34, 1185–1189 (2011). https://doi.org/10.1038/hr.2011.100.Gorostidi, M., de la Sierra, A., González-Albarrán, O. et al. Abnormalities in ambulatory blood pressure monitoring in hypertensive patients with diabetes. Hypertens Res 34, 1185–1189 (2011). https://doi.org/10.1038/hr.2011.100.Gaciong Z, Siński M, Lewandowski J. Blood pressure control and primary prevention of stroke: summary of the recent clinical trial data and meta-analyses. Curr Hypertens Rep. 2013 Dec;15(6):559–74. doi: 10.1007/s11906-013-0401-0.Gaciong Z, Siński M, Lewandowski J. Blood pressure control and primary prevention of stroke: summary of the recent clinical trial data and meta-analyses. Curr Hypertens Rep. 2013 Dec;15(6):559–74. doi: 10.1007/s11906-013-0401-0.Mackenzie IS, Rogers A, Poulter NR, Williams B, Brown MJ, Webb DJ, et al.; TIME Study Group. Cardiovascular outcomes in adults with hypertension with evening versus morning dosing of usual antihypertensives in the UK (TIME study): a prospective, randomised, open-label, blinded-endpoint clinical trial. Lancet. 2022 Oct 22;400(10361):1417–1425. doi: 10.1016/S0140-6736(22)01786-X.Mackenzie IS, Rogers A, Poulter NR, Williams B, Brown MJ, Webb DJ, et al.; TIME Study Group. Cardiovascular outcomes in adults with hypertension with evening versus morning dosing of usual antihypertensives in the UK (TIME study): a prospective, randomised, open-label, blinded-endpoint clinical trial. Lancet. 2022 Oct 22;400(10361):1417–1425. doi: 10.1016/S0140-6736(22)01786-X.SPRINT Research Group; Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, et al. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med. 2015 Nov 26;373(22):2103–16. doi: 10.1056/NEJMoa1511939.SPRINT Research Group; Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, et al. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med. 2015 Nov 26;373(22):2103–16. doi: 10.1056/NEJMoa1511939.ACCORD Study Group; Cushman WC, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr, Cutler JA, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010 Apr 29;362(17):1575–85. doi: 10.1056/NEJ-Moa1001286.ACCORD Study Group; Cushman WC, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr, Cutler JA, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010 Apr 29;362(17):1575–85. doi: 10.1056/NEJ-Moa1001286.Zhang W, Zhang S, Deng Y, Wu S, Ren J, Sun G, et al. STEP Study Group. Trial of Intensive Blood-Pressure Control in Older Patients with Hypertension. N Engl J Med. 2021 Sep 30;385(14):1268–1279. doi: 10.1056/NEJMoa2111437.Zhang W, Zhang S, Deng Y, Wu S, Ren J, Sun G, et al. STEP Study Group. Trial of Intensive Blood-Pressure Control in Older Patients with Hypertension. N Engl J Med. 2021 Sep 30;385(14):1268–1279. doi: 10.1056/NEJMoa2111437.Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998 Jun 13;351(9118):1755–62. doi: 10.1016/s0140-6736(98)04311-6.Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998 Jun 13;351(9118):1755–62. doi: 10.1016/s0140-6736(98)04311-6.Neal B, Wu Y, Feng X, Zhang R, Zhang Y, Shi J, et al. 2021 Sep 16;385(12):1067– 1077. doi: 10.1056/NEJMoa2105675.Neal B, Wu Y, Feng X, Zhang R, Zhang Y, Shi J, et al. 2021 Sep 16;385(12):1067– 1077. doi: 10.1056/NEJMoa2105675.Kannel WB. Fifty years of Framingham study contributions to understanding hypertension. J Hum Hypertens. 2000; 14:83–900. DOI: 10.1038/sj.jhh.1000949.Kannel WB. Fifty years of Framingham study contributions to understanding hypertension. J Hum Hypertens. 2000; 14:83–900. DOI: 10.1038/sj.jhh.1000949.Stamler J, Wentworth D, Neaton D. Prevalence and prognostic significance of hypercholesterolemia in men with hypertension: Prospective data on the primary screenees of the Multiple Risk Factor Intervention Trial. Am J Med. 1986; 80:33–9.Stamler J, Wentworth D, Neaton D. Prevalence and prognostic significance of hypercholesterolemia in men with hypertension: Prospective data on the primary screenees of the Multiple Risk Factor Intervention Trial. Am J Med. 1986; 80:33–9.Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. ESC Scientific Document Group. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018 Sep 1;39(33):3021–3104. doi: 10.1093/eurheartj/ehy339.Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. ESC Scientific Document Group. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018 Sep 1;39(33):3021–3104. doi: 10.1093/eurheartj/ehy339.Catalá-López F, Macías Saint-Gerons D, González-Bermejo D, Rosano GM, Davis BR, Ridao M, et al. Cardiovascular and Renal Outcomes of Renin-Angiotensin System Blockade in Adult Patients with Diabetes Mellitus: A Systematic Review with Network Meta-Analyses. PLoS Med. 2016 Mar 8;13(3): e1001971. doi: 10.1371/journal.pmed.1001971.Catalá-López F, Macías Saint-Gerons D, González-Bermejo D, Rosano GM, Davis BR, Ridao M, et al. Cardiovascular and Renal Outcomes of Renin-Angiotensin System Blockade in Adult Patients with Diabetes Mellitus: A Systematic Review with Network Meta-Analyses. PLoS Med. 2016 Mar 8;13(3): e1001971. doi: 10.1371/journal.pmed.1001971.Arnold SV, Bhatt DL, Barsness GW, Beatty AL, Deedwania PC, Inzucchi SE, et al. American Heart Association Council on Lifestyle and Cardiometabolic Health and Council on Clinical Cardiology. Clinical Management of Stable Coronary Artery Disease in Patients With Type 2 Diabetes Mellitus: A Scientific Statement From the American Heart Association. Circulation. 2020 May 12;141(19): e779-e806. doi: 10.1161/CIR.0000000000000766.Arnold SV, Bhatt DL, Barsness GW, Beatty AL, Deedwania PC, Inzucchi SE, et al. American Heart Association Council on Lifestyle and Cardiometabolic Health and Council on Clinical Cardiology. Clinical Management of Stable Coronary Artery Disease in Patients With Type 2 Diabetes Mellitus: A Scientific Statement From the American Heart Association. Circulation. 2020 May 12;141(19): e779-e806. doi: 10.1161/CIR.0000000000000766.Lewis EJ, Hunsicker LG, Bain RP, Rohde RD; The Collaborative Study Group. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329:1456–1462.Lewis EJ, Hunsicker LG, Bain RP, Rohde RD; The Collaborative Study Group. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329:1456–1462.Corrao G, Zambon A, Parodi A, Poluzzi E, Baldi I, Merlino L, et al. Discontinuation of and changes in drug therapy for hypertension among newly-treated patients: a population-based study in Italy. J Hypertens 2008; 26:819–824. DOI: 10.1097/HJH.0b013e3282f4edd7.Corrao G, Zambon A, Parodi A, Poluzzi E, Baldi I, Merlino L, et al. Discontinuation of and changes in drug therapy for hypertension among newly-treated patients: a population-based study in Italy. J Hypertens 2008; 26:819–824. DOI: 10.1097/HJH.0b013e3282f4edd7.Остроумова О. Д., Буторов В. Н., Кочетков А. И., Клепикова М. В., Головина О. В. Применение телмисартана в комбинации с моксонидином при лечении артериальной гипертонии у больных с ожирением. Кардиология и сердечно-сосудистая хирургия. 2020; 13(5):452–458. https://doi.org/10.17116/kardio202013051452.Остроумова О. Д., Буторов В. Н., Кочетков А. И., Клепикова М. В., Головина О. В. Применение телмисартана в комбинации с моксонидином при лечении артериальной гипертонии у больных с ожирением. Кардиология и сердечно-сосудистая хирургия. 2020; 13(5):452–458. https://doi.org/10.17116/kardio202013051452.Chua SK, Lai WT, Chen LC, Hung HF. The Antihypertensive Effects and Safety of LCZ696 in Patients with Hypertension: A Systemic Review and Meta-Analysis of Randomized Controlled Trials. J Clin Med. 2021 Jun 26;10(13):2824. doi: 10.3390/jcm10132824.Chua SK, Lai WT, Chen LC, Hung HF. The Antihypertensive Effects and Safety of LCZ696 in Patients with Hypertension: A Systemic Review and Meta-Analysis of Randomized Controlled Trials. J Clin Med. 2021 Jun 26;10(13):2824. doi: 10.3390/jcm10132824.Carlberg B, Samuelsson O, Lindholm LH. Atenolol in hypertension: is it a wise choice? Lancet. 2004 Nov 6–12;364(9446):1684–9. doi: 10.1016/S0140-6736(04)17355-8.Carlberg B, Samuelsson O, Lindholm LH. Atenolol in hypertension: is it a wise choice? Lancet. 2004 Nov 6–12;364(9446):1684–9. doi: 10.1016/S0140-6736(04)17355-8.Williams B, MacDonald TM, Morant S, Webb DJ, Sever P, McInnes G, et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet 2015; 386:2059–2068. doi: 10.1016/S0140-6736(15)00257-3.Williams B, MacDonald TM, Morant S, Webb DJ, Sever P, McInnes G, et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet 2015; 386:2059–2068. doi: 10.1016/S0140-6736(15)00257-3.Agarwal R, Kolkhof P, Bakris G, Bauersachs J, Haller H, Wada T, Zannad F. Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine. Eur Heart J. 2021 Jan 7;42(2):152–161. doi: 10.1093/eurheartj/ehaa736.Agarwal R, Kolkhof P, Bakris G, Bauersachs J, Haller H, Wada T, Zannad F. Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine. Eur Heart J. 2021 Jan 7;42(2):152–161. doi: 10.1093/eurheartj/ehaa736.

The authors declare that there are no conflicts of interest present.